Preview

Вопросы гематологии/онкологии и иммунопатологии в педиатрии

Расширенный поиск

Возможности терапии рецидивов и рефрактерных форм лимфомы Ходжкина у детей, подростков и молодых взрослых

https://doi.org/10.24287/1726-1708-2018-17-1-136-143

Полный текст:

Аннотация

Лимфома Ходжкина (ЛХ) - прогностически один из наиболее благоприятных вариантов злокачественных лимфопролиферативных заболеваний. В настоящее время у большинства пациентов с ЛХ удается достичь ремиссии после первой линии терапии. И даже для тех пациентов, у которых происходит рецидив или имеет место первично-рефрактерное течение ЛХ, доступны высокоэффективные опции специфической терапии второй, третьей линий лечения. Выбор варианта лечения зависит от нескольких факторов, в том числе от времени возникновения рецидива, возраста пациента, общего его состояния и предыдущих методов лечения.

Об авторах

А.В. Пшонкин
ФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России
Россия


Д.А. Евстратов
ФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России
Россия


Н.В. Мякова
ФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России
Россия


Список литературы

1. European age-standardised rates calculated by the Statistical Information Team at Cancer Research UK, 2011 using data from GLOBOCAN, IARC, version 1.2.

2. Ries L.A.G., Harkins D., Krapcho M., Mariotto A., Miller B.A., Feuer E.J., et al. SEER Cancer Statistics Review, 1975-2003. Bethesda, Md: National Cancer Institute, 2006.

3. Duggan D.B., Petroni G.R., Johnson J.L., Glick J.H., Fisher R.I., Connors J.M., et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin’s disease: a report of an intergroup trial. J Clin Oncol 2003;21 (4): 607-14.

4. Connors J.M., Klimo P., Adams G., Burns B.F., Cooper I., Meyer R.M., et al. Treatment of advanced Hodgkin’s disease with chemotherapy: comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD - A report from the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol, 1997; 15 (4): 1638-45.

5. Körholz D., Claviez A., Hasenclever D., Kluge R., Hirsch W., Kamprad F., et al. The concept of the GPOH-HD 2003 therapy study for pediatric Hodgkin's disease: evolution in the tradition of the DAL/GPOH studies. Klin Padiatr 2004; 216 (3): 150-6.

6. Diehl V., Franklin J., Pfreundschuh M., Lathan B., Paulus U., Hasenclever D., et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. N Engl J Med 2003; 348 (24): 2386-95.

7. Cavalli F.G. Hodgkin’s disease: treatment of relapsed disease. Annals of Oncology 2002; 13 (suppl 4): 159-62.

8. Keegan T.H., Clarke C.A., Chang E.T., Shema S.J., Glaser S.L. Disparities in survival after Hodgkin lymphoma: a population-based study. Cancer Causes Control 2009; 20, (10): 1881-92.

9. Gobbi P.G., Cavalli C., Federico M., Bertolino D., Di Prisco U.A., Rossi A., et al. Hodgkin disease prognosis: a directly predictive equation. Lancet 1988; 1 (8587): 675-9.

10. Colonna P., Jais J.P., Desablens B., Harousseau J.L., Briere J., Boasson M., Lemevel A., et al. Mediastinal tumor size and response to chemotherapy are the only prognostic factors in supradiaphragmatic Hodgkin disease treated by ABVD plus radiotherapy ten years results of the Paris Ouest France 81/12 trial, including 262 patients. J Clin Oncol 1996; 14: 1928-35.

11. Schellong G., Dörffel W., Claviez A., Körholz D., Mann G., Scheel-Walter H.-G., et al. Salvage therapy of progressive and recurrent Hodgkin's disease: results from a multicenter study of the pediatric DAL/GPOH-HD study group. J Clin Oncol 2005; 23 (25): 6181-9.

12. Arai S., Fanale M., de Vos S., Engert A., Illidge T., Borchmann P., Younes A., et al. Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant. Leukemia & Lymphoma 2013; 54 (11): 2531-3.

13. Buglio D., Geordakis G., Younes A. Novel small-molecule therapy for Hodgkin lymphoma. Exp Rev Anticancer therapy 2007; 7 (5): 735-40.

14. Rancea M., Monsef I., von Tresckow B., Engert A, Skoetz N. High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma. Cochrane Database Syst Rev 2013;6: CD009411.

15. Visani G., Malerba L., Stefani P., Capria S., Galieni P., Gaudio F., et al. BEAM (bendamustin, etoposide, cytarabine, melphalan) before autologous stem cell tranplantation is safe and effective for resistant/relapsed lymphoma patients. Blood 2011; 118 (12): 3419-25.

16. Tombleson R.L., Green M.R., Fancher K.M. Putting causion in TEAM: high-dose ahemotherapy with autologous HSCT for primapy central nervous system lymphoma. BoneMarrowTransplantation 2012; 47 (10): 1383-4.

17. Жуков Н.В. Использование высокодозной химиотерапии с трансплантацией клеток предшественников гемопоэз для лечения больных с неблагоприятным течением лимфомы Ходжкина / Дисс. на соиск. уч. степ. д-ра мед. наук. 2015.

18. Cocorocchio E., Peccatori F., Vanazzi A., Piperno G., Calabrese L., Botteri E., et al. High-dose chemotherapy in relapsed or refractory Hodgkin lymphoma patients: a reappraisal of prognostic factors. Hematol Oncol 2013; 31: 34-40.

19. Hazar V., Kesik V., Aksoylar S., Karakukcu M., Ozturk G., Kupesiz A., et al. Outcome of autologous hematopoietic stem cell transplantation in children and adolescents with relapsed or refractory Hodgkin's lymphoma. Pediatr Transplant 2015; 19 (7): 745-52.

20. Palmer J., Goggins T., Broadwater G., Chao N., Horwitz M., Beaven A., et al. Early post transplant (F-18) 2-fluoro-2-deoxyglucose positron emission tomography does not predict outcome for patients undergoing auto-SCT in non-Hodgkin and Hodgkin lymphoma. Bone Marrow Transplantation 2011; 46 (6): 847-51.

21. Akhtar S., Al-Sugair A.S., Abouzied M., Alkadhi Y., Dingle M., Abdelsalam M., et al. Pre-transplant FDG-PET-based survival model in relapsed and refractory Hodgkin's lymphoma: outcome after high-dose chemotherapy and auto-SCT. Bone Marrow Transplant 2013; 48 (12): 1530-6.

22. Smeltzer J.P., Cashen A.F., Zhang Q., Homb A., Dehdashti F., Abboud C.N., et al. Prognostic Significance of FDG-PET in Relapsed or Refractory Classical Hodgkin Lymphoma Treated with Standard Salvage Chemotherapy and Autologous Stem Cell Transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation 2011; 17 (11): 1646-52.

23. Phillip M., Garfin M.P., Link S.S., Donaldson R.H., Advani S.L.-F., Sandhya K., et al. Improved outcomes after autologous bone marrow transplantation for children with relapsed or refractory Hodgkin lymphoma: twenty years experience at a single institution. BiolBloodMarrowTransplant 2015; 21 (2): 326-34.

24. Жуков Н.В. Первичное резистентное течение и рецидивы лимфомы Ходжкина. Предотвратимые потери при «самом излечимом» гемобластозе. Российский журнал детской гематологии и онкологии 2015; 2 (2): 60-71.

25. Josting A., Franklin J., May M., Koch P., Beykirch M.K., Heinz J., et al. New prognostic score, based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2002; 20: 221-30.

26. Bierman P.J., Lynch J.C., Bociek R.G., Whalen V.L., Kessinger A., Vose J.M., et al. The International Prognostic factors project score for advanced Hodgkin's disease is useful for predicting outcome of autologous stem cell tranplantation. Ann Oncol 2002; 13: 1270-7.

27. Perales M.A., Ceberio I., Armand P., Burns L.J., Chen R., Cole P.D., et al. Role of cytotoxictherapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: guidelines from the AmericanSociety for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation 2015; 21 (6): 971-83.

28. Thomson K.J., Peggs K.S., Smith P., Cavet J., Hunter A., Parker A., et al. Superiority ofreduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin’s lymphoma following autologousstem cell transplantation. Bone Marrow Transplantation 2008; 41 (9): 765-70.

29. Castagna L., Sarina B., Todisco E., Magagnoli M., Balzarotti M., Bramanti S., et al. Allogeneic stem cell transplantation compared with chemotherapy for poor-risk Hodgkin lymphoma. Biology of Blood and Marrow Transplantation 2009;15 (4): 432-38.

30. Sureda A., Robinson S., Canals C., Carella A.M., Boogaerts M.A., Caballero D., et al. Reduced -intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin’s lymphoma: an analysis from the lymphoma working party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008; 26 (3): 455-62.

31. Passweg J.R., Baldomero H., Gratwohl A., Bregni M., Cesaro S., Dreger P., et al. The EBMT activity survey: 1990-2010. Bone Marrow Transplantation 2012; 47 (7): 906-23.

32. Burroughs L.M., O’Donnell P.V., Sandmaier B.M., Storer B.E., Luznik L., Symons H.J., et al. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biology of Blood and Marrow Transplantation 2008; 14 (11): 1279-87.

33. Younes A., Carbone A. CD30/CD30 ligand and CD40/CD40 ligand in malignant lymphoid disorders. Int J Biol Markers 1999; 14 (3): 135-43.

34. Younes A., Aggarwall B.B. Clinical implications of the tumor necrosis factor family in benign and malignant hematologic disorders. Cancer 2003; 98 (3): 458-67.

35. Ansell S.M., Horwitz S.M., Engert A., Dad Khan K., Lin T., Strair R., et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin’s lymphoma and anaplastic large-cell lymphoma. J Clin Oncol 2007; 25 (19): 2764-9.

36. Oflazoglu E., Kissler K.M., Sievers E.L., Grewal I.S., Gerber H.-P. Combination of the anti-CD30-auristatin-E antibody drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma. Br J Haematol 2008; 142 (1): 69-73.

37. Younes A., Gopal A.K., Smith S.E. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012; 30 (18): 2183-9.

38. Moskowitz C.H., Nademanee A., Masszi T., Agura E., Holowiecki J., Abidi M.H., et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, doubleblind, placebo-controlled, phase 3 trial. Lancet 2015; 385 (9980): 1853-62.

39. Семенова А.А. Бендамустин в терапии неходжкинских лимфом. Современная онкология, 2012; 2: 10-12.

40. Moskowitz A.J., Hamlin P.A., Perales M.-A., Gerecitano J., Horwitz S.M., Matasar M.J., et al. Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. J Clin Oncol 2013; 31 (4): 456-60.

41. Kalac M., Lue J.K., Lichtenstein E., Turenne I., Rojas C., Amengual J.E., et al. Brentuximab vedotin and bendamustine produce high complete response rates in patients with chemotherapy refractory Hodgkin lymphoma. Br J Haematol 2016.doi:10.1111/bjh.14449.

42. Younes A., Sureda A., Ben-Yehuda D., Zinzani P.L., Ong T.-C., Miles Prince H., et al. Panobinostat in patients with relapsed/refractory Hodgkin’s lymphoma after autologous stem-cell transplantation: results of a phase II study. J Clin Oncol 2012; 30 (18): 2197-03.

43. Guarini A., Minoia C., Giannoccaro M., Rana A., Iacobazzi A., Lapietra A., et al. mTOR as a target of everolimus in refractory/relapsed Hodgkin Lymphoma. Cur Med Chem 2012; 19 (7): 945-54.

44. Johnston P.B., Inwards D.J., Colgan J.P., LaPlant B.R., Kabat B.F., Habermann T.M., et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol 2010; 85 (5): 320-4.

45. Ramchandren R. Advances in the treatment of relapsed or refractory Hodgkin’s lymphoma. The Oncologist 2012; 17 (3): 367-76.

46. Boll B., Fuchs M., Reiners K.S., Engert A., Borchmann P. Lenalidomide in patients with relapsed or refractory Hodgkin lymphoma. Blood 2010; 116; abst 2828.

47. Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nature Rev Cancer 2012; 12 (4): 252-64.

48. Ansell S.M., Lesokhin A.M., Borrello I., Halwani A., Scott E.C., Gutierrez M., et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. New Engl J Med 2015; 372 (4): 311-9.

49. Moskowitz C.H., Ribrag V., Michot J.M. PD-1 Blockade with the monoclonal antibody Pembrolizumab (MK-3475) in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: preliminary results from a Phase 1B study (KEYNOTE-013). Blood 2014; 124 (21): 290.


Для цитирования:


Пшонкин А., Евстратов Д., Мякова Н. Возможности терапии рецидивов и рефрактерных форм лимфомы Ходжкина у детей, подростков и молодых взрослых. Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2018;17(1):136-143. https://doi.org/10.24287/1726-1708-2018-17-1-136-143

For citation:


Pshonkin A.V., Evstratov D.A., Myakova N.V. Hodgkin's lymphoma relapses and refractory forms therapy variants in children, adolescents and young adults. Pediatric Hematology/Oncology and Immunopathology. 2018;17(1):136-143. (In Russ.) https://doi.org/10.24287/1726-1708-2018-17-1-136-143

Просмотров: 37


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1726-1708 (Print)
ISSN 2414-9314 (Online)